Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unbound Cloxacillin Concentrations During Continuous Infusion
2023-510423-30-00Phase 4Authorised
- Sponsor
- Region Västmanland
- Start
- Jul 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cloxacillin in Staphylococcus aureus infection, sponsored by Region Västmanland. Primary endpoint: Total and free (unbound) cloxacillin concentration over time. Planned start Jul 2025; status: authorised.
02
Drugs
cloxacillin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on 2023-510423-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510423-30-00.